VISCHER advised Anaveon on the deal.Anaveon AG, a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 110m Series B financing led by incoming investor Forbion,…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
